En español
NIDA

Methamphetamine

References

  1. Chang, L.; Alicata, D.; Ernst, T.; and Volkow, N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 102(Suppl 1):16–32, 2007.
  2. Chang, L.; Ernst, T.; Speck, O.; and Grob, C.S. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry 162:361–369, 2005.
  3. Ellis, R.J.; Childers, M.E.; Cherner, M.; Lazzaretto, D.; Letendre, S.; and the HIV Neurobehavioral Research Center Group. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 188(12):1820–1826, 2003.
  4. Fairbairn, N.; Kerr, T.; Milloy, M.-J.; Zhang, R.; Montaner, J.; and Wood, E. Crystal methamphetamine injection predicts slower HIV RNA suppression among injection drug users. Addict Beh 36(7):762–763, 2011.
  5. Gavrilin, M.A.; Mathes, L.E.; and Podell, M. Methamphetamine enhances cellassociated feline immunodeficiency virus replication in astrocytes. J Neurovirol 8:240–249, 2002.
  6. Huber, A.; Ling, W.; Shoptaw, S.; Gulati, V.; Brethen, P.; and Rawson, R. Integrating treatments for methamphetamine abuse: A psychosocial perspective. J Addict Dis 16(4):41–50, 1997.
  7. Johnston, L.D.; O’Malley, P.M.; Bachman, J.G.; and Schulenberg, J.E. Monitoring the future: National results on drug use: 2012 overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan, 2013. Available at: http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2012.pdf. Last accessed March 18, 2013.
  8. Kiblawi, Z.N.; Smith, L.M.; LaGasse, L.L.; Derauf, C.; Newman, E.; Shah, R.; Arria, A.; Huestis, M.; DellaGrotta, S.; Dansereau, L.M.; Neal, C.; and Lester, B. The effect of prenatal methamphetamine exposure on attention as assessed by continuous performance tests: Results from the Infant Development, Environment, and Lifestyle study. J Dev Behav Pediatr 34(1):31–37, 2013.
  9. Kuehn, B.M. Meth use linked to risk of Parkinson disease. JAMA 306:814, 2011.
  10. London, E.D.; Simon, S.L.; Berman, S.M.; Mandelkern, M.A.; Lichtman, A.M.; Bramen, J.; Shinn, A.K.; Miotto, K.; Learn, J.; Dong, Y.; Matochik, J.A.; Kurian, V.; Newton, T.; Woods, R.; Rawson, R.; and Ling, W. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61:73–84, 2004.
  11. Morgenthaler, T.I.; Kapur, V.K.; Brown, T.; Swick, T.J.; Alessi, C.; Aurora, R.N.; Boehlecke, B.; Chesson, A.L.; Friedman, L.; Maganti, R.; Owens, J.; Pancer, J.; and Zak, R. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. An American Academy of Sleep Medicine Report. Sleep 30(12):1705–1711, 2007.
  12. National Institute on Drug Abuse. Drugs of Abuse and Related Topics: Methamphetamine. Available at: http://www.drugabuse.gov/DrugPages/Methamphetamine.html. Last accessed March 18, 2013.
  13. National Institute on Drug Abuse. Epidemiologic Trends in Drug Abuse: Proceedings of the Community Epidemiology Work Group, Highlights and Executive Summary, June 2012. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2012. Avalable at: http://www.drugabuse.gov/sites/default/files/cewg_june_2012_vol1_508.pdf. Last accessed September 9, 2013.
  14. National Institute on Drug Abuse. Methamphetamine abuse linked to impaired cognitive and motor skills despite recovery of dopamine transporters. NIDA Notes 17(1), 2002. Available at: http://archives.drugabuse.gov/NIDA_Notes/NNVol17N1/Methamphetamine.html. Last accessed March 22, 2013.
  15. National Institute on Drug Abuse. Methamphetamine abusers show increased distractibility. NIDA Notes 22(3), 2009. Available at: http://www.drugabuse.gov/news-events/nida-notes/2009/04/methamphetamine-abusers-show-increased-distractibility. Last accessed March 22, 2013.
  16. National Institute on Drug Abuse. Methamphetamine turns helper cells into destroyers. NIDA Notes 22(5), 2009. Available at: http://www.drugabuse.gov/news-events/nida-notes/2009/11/methamphetamine-turns-helper-cells-destroyers. Last accessed March 22, 2013.
  17. Petry, N.M.; Peirce, J.M.; Stitzer, M.L.; Blaine, J.; Roll, J.M.; Cohen, A.; Obert, J.; Killeen, T.; Saladin, M.E.; Cowell, M.; Kirby, K.C.; Sterling, R.; Royer- Malvestuto, C.; Hamilton, J.; Booth, R.E.; Macdonald, M.; Liebert, M.; Rader, L.; Burns, R.; DiMaria, J.; Copersino, M.; Stabile, P.Q.; Kolodner, K.; and Li, R. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: A National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry 62(10):1148–1156, 2005.
  18. The RAND Corporation. The economic cost of methamphetamine use in the United States, 2005. The RAND Corporation, 2009. Available at: http://www.rand.org/content/dam/rand/pubs/monographs/2009/RAND_MG829.pdf. Last accessed March 22, 2013.
  19. Rawson, R.A.; Marinelli-Casey, P.; Anglin, M.D.; Dickow, A.; Frazier, Y.; Gallagher, C.; Galloway, G.P.; Herrell, J.; Huber, A.; McCann, M.J.; Obert, J.; Pennell, S.; Reiber, C.; Vandersloot, D.; and Zweben, J. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 99:708–717, 2003.
  20. Rippeth, J.D.; Heaton, R.K.; Carey, C.L.; Marcotte, T.D.; Moore, D.J.; Gonzalez, R.; Wolfson, T.; and Grant, I. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 10:1–14, 2004.
  21. Sekine, Y.; Ouchi, Y.; Sugihara, G.; Takei, N.; Yoshikawa, E.; Nakamura, K.; Iwata, Y.; Tsuchiya, K.J.; Suda, S.; Suzuki, K.; Kawai, M.; Takebayashi, K.; Yamamoto, S.; Matsuzaki, H.; Ueki, T.; Mori, N.; Gold, M.S.; and Cadet, J.L. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 28(22):5756–5761, 2008.
  22. Smith, L.M.: LaGasse, L.L.; Derauf, C.; Grant, P.; Shah, R.; Arria, A.; Huestis, M.; Haning, W.; Strauss, A.; Della Grotta, S.; Fallone, M.; Liu, J.; and Lester, B.M. Prenatal methamphetamine use and neonatal neurobehavioral outcome. Neurotoxicol Teratol 30(1):20–28, 2008. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2358984/. Last accessed April 9, 2013.
  23. Smith, L.M.; LaGasse, L.L.; Derauf, C.; Grant, P.; Shah, R.; Arria, A., Huestis, M.; Haning, W.; Strauss, A.; Della Grotta, S.; Liu, J.; and Lester, B.M. The Infant Development, Environment, and Lifestyle Study: Effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics 118(3):1149–1156, 2006.
  24. Snider, S.E.; Hendrick, E.S.; and Beardsley, P.M. Glial cell modulators attenuate methamphetamine self-administration in the rat. Eur J Pharmacol 701(1–3):124–130, 2013.
  25. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, 2013. Available at: http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm. Last accessed September 9, 2013.
  26. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Drug Abuse Warning Network: 2011. National estimates of drug-related emergency department visits, HHS Publication No. SMA 13-4760, DAWN Series D-39. Rockville, MD: U.S Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, 2013 Available at: http://www.samhsa.gov/data/2k13/DAWN2k11ED/DAWN2k11ED.htm. Last accessed September 09, 2013.
  27. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Drug Abuse Warning Network: 2012. DAWN 2010 Emergency Department Excel Files–National Tables. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, 2012. Available at: http://www.samhsa.gov/data/DAWN.aspx. Last accessed March 18, 2013.
  28. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Treatment Episode Data Set (TEDS): 2001–2011. National Admissions to Substance Abuse Treatment Services, BHSIS Series S-65, HHS Publication No. (SMA) 13-4772 Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, 2013. Available at: http://www.samhsa.gov/data/2k13/TEDS2011/TEDS2011NAck.htm. Last accessed September 9, 2013.
  29. Thompson, P.M.; Hayashi, K.M.; Simon, S.L.; Geaga, J.A.; Hong, M.S.; Sui, Y.; Lee, J.Y.; Toga, A.W.; Ling, W.; and London, E.D. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24:6028–6036, 2004.
  30. Toussi, S.S.; Joseph, A.; Zheng, J.H.; Dutta, M.; Santambrogio, L.; and Goldstein, H. Short communication: Methamphetamine treatment increases in vitro and in vivo HIV replication. AIDS Res Hum Retroviruses 25(11):1117–1121, 2009.
  31. U.S. Environmental Protection Agency. Voluntary guidelines for methamphetamine laboratory cleanup, August 2009. Available at: http://www.epa.gov/osweroe1/meth_lab_guidelines.pdf. Last accessed March 22, 2013.
  32. U.S. Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers. FDA asks attention-deficit hyperactivity disorder (ADHD) drug manufacturers to develop patient medication guides. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm107918.htm. Last accessed March 22, 2013.
  33. Volkow, N.D.; Chang, L.; Wang, G-J.; Fowler, J.S.; Franceschi, D.; Sedler, M.; Gatley, S.J.; Miller, E.; Hitzemann, R.; Ding, Y-S.; and Logan, J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21(23):9414–9418, 2001.
  34. Volkow, N.D.; Chang, L.; Wang G-J.; Fowler, J.S.; Leonido-Yee, M.; Franceschi, D.; Sedler, M.J; Gatley, S.J.; Hitzemann, R.; Ding, Y-S.; Logan, J.; Wong, C.; and Miller, E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158(3):377– 382, 2001.
  35. Wang G-J; Volkow, N.D.; Chang, L.; Miller, E.; Sedler, M.; Hitzemann, R.; Zhu, W.; Logan, J.; Ma, Y.; and Fowler, J.S. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry 161(2):242–248, 2004.
  36. Wouldes, T.; LaGasse, L.; Sheridan, J.; and Lester, B. Maternal methamphetamine use during pregnancy and child outcome: What do we know? N Z Med J 117:U1180, 2004.

This page was last updated September 2013

Get this Publication

NIDA Publications

NIDA Notes: The Latest in Drug Abuse Research

​Research Reports

This series of reports simplifies the science of research findings for the educated lay public, legislators, educational groups, and practitioners. The series reports on research findings of national interest.